Mastocytosis
A rare neoplastic disorder characterized by a clonal proliferation of MAST CELLS, associated with KIT-D816 mutations, and accompanied by aberrant mast cell activation. The abnormal increase of MAST CELLS may occur in only the skin (MASTOCYTOSIS, CUTANEOUS), in extracutaneous tissues involving multiple organs (MASTOCYTOSIS, SYSTEMIC), or in solid tumors (MASTOCYTOMA).
Subtype terms (4)
More specific conditions that are subtypes of Mastocytosis in the MeSH hierarchy.
- Mast-Cell Sarcoma
- Mastocytoma
- Mastocytosis, Cutaneous
4 drugs (3 approved, 1 experimental)
- Mastocytosis, Systemic
29 drugs (19 approved, 10 experimental)
Drugs by status
Approved for this indication (3)
Phase 3 trials (4)
Phase 2 trials (12)
Phase 1 trials (5)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (6)
Organization Involved with Phase 2 Indications (19)
- Bristol-Myers Squibb
- Novartis
- Blueprint Medicines Corporation
- JADO Technologies GmbH
- Patara Pharma
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Stanford University
- Thomas Jefferson University
- University of Groningen
- University of Bologna
- University of Naples Frederico II
- University of Minnesota
- City of Hope National Medical Center
- University of Texas at Houston
- Leo Pharma
- Gemin X
- University of Picardie Jules Verne
Organization Involved with Phase 1 Indications (2)